These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31381891)

  • 1. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes.
    Garg V; Verma S; Connelly K
    Prog Cardiovasc Dis; 2019; 62(4):349-357. PubMed ID: 31381891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcome trials of the newer anti-diabetic medications.
    Acharya T; Deedwania P
    Prog Cardiovasc Dis; 2019; 62(4):342-348. PubMed ID: 31442511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
    O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
    Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
    Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
    Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
    Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile.
    Muzurović E; Mikhailidis DP
    Expert Opin Pharmacother; 2020 Dec; 21(17):2125-2135. PubMed ID: 32697112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020.
    Sherrill CH; Hwang AY
    Ann Pharmacother; 2024 Mar; 58(3):248-254. PubMed ID: 37323006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
    Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
    Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States.
    Al-Kindi SG; Janus SE; Neeland IJ; Rajagopalan S
    J Diabetes Complications; 2022 Jul; 36(7):108224. PubMed ID: 35667964
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and Cardiovascular Safety of SGLT2 Inhibitors.
    Fernandez CJ; Nevins AG; Nawaz S; Nazir T; Hanna FWF
    Curr Drug Saf; 2021; 16(2):178-196. PubMed ID: 33006538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.
    Dey AK; Groenendyk J; Mehta NN; Gourgari E
    Clin Cardiol; 2019 Mar; 42(3):406-412. PubMed ID: 30635924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients.
    Fadah K; Alashi A; Deoker A
    Curr Cardiol Rep; 2022 Jan; 24(1):17-22. PubMed ID: 35000149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.